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Abstract
STAT3 is a transcription factor implicated in renal fibrotic injury, but the role of STAT3 in mesenchymal
stem cell (MSC)-induced renoprotection during renal fibrosis remains unknown. We hypothesized that
MSCs protect against obstruction-induced renal fibrosis by downregulating STAT3 activation and STAT3-
induced matrix metalloproteinase-9 (MMP-9) expression. Male Sprague-Dawley rats underwent renal
arterial injection of vehicle or MSCs (1 × 10 /rat) immediately before sham operation or induction of
unilateral ureteral obstruction (UUO). The kidneys were harvested after 4 wk and analyzed for collagen I
and III gene expression, collagen deposition (Masson’s trichrome), fibronectin, α-smooth muscle actin,
active STAT3 (p-STAT3), MMP-9, and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1)
expression. In a separate arm, the STAT3 inhibitor S3I-201 (10 mg/kg) vs. vehicle was administered to rats
intraperitoneally just after induction of UUO and daily for 14 days thereafter. The kidneys were harvested
after 2 wk and analyzed for p-STAT3 and MMP-9 expression, and collagen and fibronectin deposition.
Renal obstruction induced a significant increase in collagen, fibronectin, α-SMA, p-STAT3, MMP-9, and
TIMP-1 expression while exogenously administered MSCs significantly reduced these indicators of
obstruction-induced renal fibrosis. STAT3 inhibition with S3I-201 significantly reduced obstruction-
induced MMP-9 expression and tubulointerstitial fibrosis. These results demonstrate that MSCs protect
against obstruction-induced renal fibrosis, in part, by decreasing STAT3 activation and STAT3-dependent
MMP-9 production.
Keywords: mesenchymal stem cell, signal transducers and activators of transcription, matrix
metalloproteinases, kidney, unilateral ureteral obstruction, epithelial mesenchymal transition, ureteral
obstruction, matrix metalloproteinase-9, signal transducer and activator of transcription-3
ආൾඌൾඇർඁඒආൺඅ ඌඍൾආ ർൾඅඅඌ (MSCs) are nonembryonic stem cells of mesodermal origin that have the
capacity to differentiate into cells of connective tissue lineage and have a unique ability to home or migrate
to injured tissue (1, 8, 28). MSCs are anti-inflammatory and can inhibit immune cell activation and
proliferation, as well as the production of proinflammatory mediators (1, 8, 28). Several studies have
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demonstrated that MSCs can protect against acute and chronic renal injury (1, 8, 28), and, while the
mechanism of MSC-induced renal protection remains unknown, recent studies suggest that a significant
component of MSC’s protective and reparative function resides in their paracrine activity. MSCs can
secrete a number of growth factors and cytokines that are important for angiogenesis and cytoprotection
and have been demonstrated to prevent tubulointerstitial fibrosis during chronic unilateral ureteral
obstruction (UUO) (2, 5, 9).
Progressive tubulointerstitial fibrosis is a prominent characteristic of obstruction-induced renal injury and
represents the final common pathway for nearly all forms of chronic kidney disease (CKD). Interstitial
fibrosis is characterized by a prominent inflammatory cell infiltrate, fibroblast proliferation, and an
imbalance in extracellular matrix (ECM) synthesis and degradation (7, 15, 25). The release of a number of
cytokines and growth factors during obstructive renal injury induces profibrotic signaling, reduces ECM
degradation, and stimulates renal tubular cell epithelial mesenchymal transition (EMT), a process by which
tubular epithelial cells (TECs) undergo a phenotypic transformation into matrix-producing fibroblasts (11,
29, 30, 44).
Matrix metalloproteinases (MMPs) are a large family of endopeptidases that proteolyze all components of
ECM and are critical for ECM remodeling and matrix homeostasis. MMP activity is regulated by the tissue
inhibitors of matrix metalloproteinases (TIMPs), a family of specific endogenous inhibitors of MMPs that
bind MMPs in a 1:1 stoichiometry. MMPs are traditionally believed to have an antifibrotic role in the
development and progression of CKD because of their proteolytic activity (33); however, recent studies
have demonstrated that MMPs, particularly MMP-9, can stimulate renal fibrosis and EMT during
obstructive renal injury (33, 41). MMP-9 has been shown to mediate EMT in tubular epithelial cells in vitro
(34, 45), and recent reports link MMP-9 expression in mammary epithelial cells and dermal fibroblasts to
STAT3 activation (6, 40).
The JAK/STAT signaling pathway has increasingly been implicated in the pathophysiology of fibrotic renal
disease (19), and STAT3 has been demonstrated to have a significant role in obstruction-induced
tubulointerstitial fibrosis and profibrotic signaling in TECs in vitro (20, 23). Whereas MSCs have been
demonstrated to improve left ventricular function and activate cardiac repair mechanisms in the diseased
heart through STAT3 signaling (27), the relationship between STAT3 and MMP-9 during renal obstruction
and the role of STAT3 and MMP-9 in MSC-induced renoprotection remains unknown. We therefore
hypothesized that MSCs protect against obstruction-induced renal fibrosis by reducing STAT3 activation
and STAT3-dependent MMP-9 production. To study this, renal cortical collagen I and III gene expression,
fibronectin, α-smooth muscle actin (α-SMA), active STAT3 (p-STAT3), MMP-9, and TIMP-1 expression
were examined in Sprague-Dawley rats using a well-established model of UUO. In addition, the effect of
STAT3 inhibition on obstruction-induced MMP-9 expression and tubulointerstitial fibrosis was evaluated.
MATERIALS AND METHODS
The animal protocol was
reviewed and accepted by the Animal Care and Research Committee of the Indiana University School of
Medicine. Adult male Sprague-Dawley rats weighing 250–300 g were acclimated and maintained on a
standard pellet diet for 1 wk before experiment initiation. The animals were anesthetized with isoflurane
inhalation. Human MSCs were purchased from Cambrex Bio Science Walkersville (Walkersville, MD) and
cultured in MSC Basal Medium (Lonza, Walkersville, MD) containing 10% fetal bovine serum for 14 days
before injection. According to the manufacturer, cells are positive for CD105, CD166, CD29, and CD44
and negative for CD14, CD34, and CD45. MSCs were labeled with the PKH26 red fluorescence cell linker
kit (Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s protocol, just before injection.
Following the induction of anesthesia, rats underwent renal arterial injection of either vehicle or MSCs (1 ×
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10 /rat) according to the techniques previously described (16). Subsequently, the left ureter was completely
ligated with 5–0 silk suture. Sham-operated rats underwent an identical surgical procedure without ureteral
ligation. The animals underwent renal arterial injection of MSCs or vehicle immediately before UUO and
were subjected to 4 wk of obstruction vs. sham operation. Four weeks postoperatively, rats were
anesthetized, the left kidneys were removed and snap-frozen in liquid nitrogen, and the animals were
subsequently killed. The animals were divided into four experimental groups (6 animals/group) as follows:
sham operation, UUO plus vehicle, sham plus MSCs, and UUO plus MSCs.
In the separate arm, the specific STAT3 inhibitor S3I-201 (10 mg/kg; EMD Chemicals, San Diego, CA)
(23) or vehicle (0.05% DMSO) was administered to rats intraperitoneally just after induction of UUO and
daily for 14 days thereafter. Rats were subjected to 2 wk of obstruction vs. sham operation. After 2 wk, rats
were killed, the left kidneys were removed and snap-frozen in liquid nitrogen, and the animals were
subsequently killed. The animals were divided into three experimental groups (6 animals/group) as follows:
sham operation, UUO plus vehicle, and UUO plus S3I-201.
A portion of each renal cortex was homogenized after the samples had been
diluted in 10 vol of homogenate buffer/g of tissue [10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EGTA,
0.1 mM DTT, and Complete Protease Inhibitor tabs (Roche Diagnostics, Indianapolis, IN)] using a
vertishear tissue homogenizer. Renal homogenates were then centrifuged at 3,000 g for 15 min at 4°C, and
the supernatants were stored at −80°C until the ELISAs or Western blots could be performed.
Total RNA was extracted from renal cortical tissue by homogenization in Trizol (GIBCO-
BRL, Gaithersburg, MD) and then isolated by precipitation with chloroform and isopropanol. Total RNA
(0.5 μg) was subjected to cDNA synthesis using iScript (Bio-Rad, Hercules, CA). The cDNA from each
sample was analyzed for collagen 1a2 (Rn01526724_m1), collagen 3a1 (Rn01437681_m1), and MMP-9
(Rn00579162_m1) using TaqMan gene expression assay (RT-PCR; Applied Biosystems, Foster City, CA).
FAM/Dye MGB-labeled probes for rat β−actin (Applied Biosystems) served as endogenous controls.
Tissue sections (4 μm) were deparaffinized and rehydrated with alcohol.
The slides were then washed in distilled water and stained in Weigert’s iron hematoxylin working solution
for 10 min. The slides were washed and stained in Biebrich scarlet-acid fuchsin solution for 15 min. The
slides were then rewashed and differentiated in phosphomolybdic-phosphotungstic acid solution for 15
min. The tissue sections were then transferred directly to aniline blue solution for 5–10 min, rinsed, and
differentiated in 1% acetic acid solution for 2–5 min. The slides were dehydrated, cleared in xylene, and
mounted.
Renal sections (4 μm) were harvested from each sample, fixed in
4% PFA/PBS, and placed in paraffin. After deparaffinization, antigen retrieval was conducted on slides.
Sections were exposed to a Biocare reveal decloaker for 30 min at 90°C, washed in TBS three times,
incubated for 30 min in rodent block M blocking solution, and incubated for 5 min in background punisher.
Slides were then incubated with anti-fibronectin antibody ab2413 (1:200; Abcam Cambridge, MA) or anti-
α−SMA antibody (1A4 clone) (1:200; Santa Cruz, Dallas, TX) for 2 h at room temperature (RT). Slides
were washed three times in TBS and incubated for 45 min at RT with a 4+ HRP detection kit (Biocare
Medical, Concord, CA). The slides were counterstained with CAT hematoxylin. To assess immunostaining
specificity, adjacent sections were incubated without primary antibody and processed using identical
conditions. Slides were mounted and imaged at ×400 using a Nikon Eclipse microscope and Nikon digital
imager (Nikon, Tokyo, Japan).
Tissue sections (4 μm) were deparaffinized and dehydrated with xylene and
alcohol. Antigen was retrieved by incubating the cells with proteinase K for 20 min in an oven. The tissues
were then blocked with 1% bovine serum albumin. Slides were incubated with an anti-p-STAT3(Tyr )
6
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antibody (1:25; Cell Signaling, Danvers, MA) for 30 min. The slides were washed in TBS and incubated
with the secondary antibody (goat anti-rabbit; Dako EnVision, Carpinteria, CA) for 30 min. Peroxidase-
stained sections were then developed with 3,3′-diaminobenzidine and counterstained with hemalum.
Sections incubated without primary antibody exhibited no staining.
Protein extracts from homogenized samples (30 μg/lane) were subjected to SDS-
PAGE on a Tris-glycine gel and transferred to a polyvinylidene fluoride membrane. Immunoblotting was
performed by incubating each membrane in 5% dry milk for 1 h, followed by incubation with an anti-
α-SMA monoclonal antibody (clone 1A4, 1:500 overnight at 4°C; R&D Systems, Minneapolis, MN), an
anti-p-STAT3 antibody (1:200 overnight at 4°C; Cell Signaling), or an anti-fibronectin antibody (1:200
overnight at 4°C; Santa Cruz Biotechnology). After being washed three times in TBST, each membrane
was incubated for 1 h at RT with a peroxidase-conjugated secondary antibody (1:2,000). Equivalent protein
loading in each lane was confirmed by stripping and reblotting each membrane for GAPDH (1:10,000 for
30 min at RT, secondary 1:10,000 for 30 min at RT; Biodesign, Saco, ME). The membranes were
developed using enhanced chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ), and the
density of each band was determined using National Institutes of Health image analysis software and
expressed as a percentage of GAPDH density.
Renal cortical homogenate total MMP-9 and TIMP-1 protein levels were determined using an
ELISA. The ELISA was performed by adding 100 μl of each sample to wells in a 96-well plate of a rat
ELISA kit (MMP-9 and TIMP-1; R&D Systems). Each ELISA was performed according to manufacturer
instructions. Final results were expressed as nanograms of MMP-9 or TIMP-1 per milligram protein.
Data are presented as means ± SE. Differences at the 95% confidence level were
considered significant. The experiment groups were compared using one-way ANOVA with post hoc
Bonferroni-Dunn (JMP 11).
RESULTS
To evaluate the effect of exogenously delivered MSCs on
obstruction-induced renal fibrosis, collagen mRNA expression and renal cortical Masson’s trichrome
staining were evaluated in response to 4 wk of obstruction. Collagen I and collagen III mRNA expression (
Fig. 1, A and B) and tubulointerstitial collagen deposition (Fig. 1C) significantly increased in response to 4
wk of obstruction; however, obstruction-induced collagen expression and deposition were markedly
reduced in the presence of exogenous MSCs.
Similarly, fibronectin and α-SMA expression were significantly increased in response to 4 wk of
obstruction (Fig. 2) but reduced to near sham treatment levels in the presence of MSCs. Fibronectin
deposition primarily localized to the glomerulus in sham-treated animals and MSC-treated animals
subjected to obstruction, whereas animals exposed to 4 wk of obstruction in the absence of MSCs
demonstrated increased fibronectin deposition in the tubulointerstitial compartment and glomerulus. Renal
cortical α-SMA deposition was also significantly increased in response to 4 wk of obstruction and exhibited
a tubulointerstitial pattern of distribution in obstructed samples with only arteriolar staining evident in sham
samples (Fig. 2). In contrast, α-SMA deposition in the tubuloninterstitial compartment was minimal in
MSC-treated animals exposed to 4 wk of obstruction (Fig. 3).
Renal cortical MMP-9 protein and mRNA levels were minimal in sham-
treated animals but increased significantly in response to 4 wk of obstruction. In the presence of
exogenously delivered MSCs, obstruction-induced MMP-9 levels were dramatically reduced to near sham
treatment levels (Fig. 4, A and B). Similarly, TIMP-1 expression was significantly increased in response to
4 wk of obstruction but reduced in the presence of MSCs (Fig. 4C). Whereas TIMP-1 expression was
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significantly reduced in the presence of MSCs, an analysis of the ratio of TIMP-1/MMP-9 expression in
each sample demonstrated over an eightfold increase in TIMP-1/MMP-9 expression in obstructed animals
treated with MSCs compared with vehicle-treated animals (Fig. 4D). These findings suggest that MSCs
protect against obstruction-induced renal fibrosis by dramatically reducing MMP-9 expression and causing
a significant increase in the ratio of TIMP-1 to MMP-9 expression.
To evaluate the effect of MSCs on obstruction-induced STAT3 activation, p-STAT3
expression and the immunohistochemical localization of p-STAT3 were evaluated in renal cortical tissue
samples. p-STAT3 expression and the number of nuclei staining positive for p-STAT3 increased
significantly in response to 4 wk of obstruction (Fig. 5, A and B), with nuclear p-STAT3 staining localizing
primarily to renal tubular epithelial cells and interstitial cells. In contrast, obstruction-induced p-STAT3
expression and nuclear staining for p-STAT3 were significantly reduced in the presence of exogenously
delivered MSCs.
To evaluate the relationship between
MMP-9 expression and STAT3 activation, MMP-9 expression levels were evaluated in animals subjected to
2 wk of UUO in the presence of STAT3 inhibition (S3I-201) or vehicle. S3I-201 significantly reduced
STAT3 activation in response to obstruction (Fig. 6A) and, further, was demonstrated to significantly
reduce renal MMP-9 expression levels in response to obstruction (Fig. 6B). These findings suggest that
obstruction-induced MMP-9 expression is, in part, dependent on STAT3 activation.
To evaluate the impact of STAT3
inhibition on obstruction-induced tubulointerstitial fibrosis and the deposition of collagen and fibronectin,
renal cortical tissue sections were stained for collagen with Masson’s trichrome and for fibronectin. Both
collagen deposition and fibronectin staining were significantly increased in the tubulointerstitial
compartment of the kidney in response to 2 wk of obstruction (Fig. 7). Animals exposed to STAT3
inhibition, however, demonstrated a marked reduction in collagen and fibronectin deposition in response to
obstruction.
DISCUSSION
Mesenchymal stem cell-based therapies have been shown to confer renal protection in several models of
acute kidney injury (AKI) (10, 12–14, 21, 35, 36, 46), and early clinical trials have demonstrated the safety
and efficacy of MSCs in protecting against renal dysfunction and reducing both the length of stay and need
for hospital readmission in cardiac surgery patients at high risk for postoperative AKI (37, 42). A decreased
incidence of acute rejection has also been demonstrated in patients receiving MSCs at the time of kidney
transplantation (32). Although MSC therapy is becoming an attractive strategy for renal repair, most
clinical trials involve only early phases of kidney disease (28), and the potential of MSC-based therapy to
prevent or ameliorate CKD is only beginning to be elucidated. Several recent animal studies show the
capacity of exogenously administered MSCs to dramatically reduce tubulointerstitial fibrosis, preserve
peritubular capillary density, and prevent epithelial mesenchymal transition in multiple different models of
chronic renal injury (2, 3, 5, 22, 26, 31, 38). Our results support these observations and demonstrate a
significant reduction in obstruction-induced collagen I and III mRNA expression, collagen deposition,
fibronectin and α-SMA expression, and fibronectin and α-SMA deposition in the kidney in the presence of
MSCs.
Whereas the specific mechanism of MSC-induced renoprotection remains unknown, accumulating
evidence suggests that exogenously administered stem cells mediate their renoprotective effect through
paracrine activity, since MSC-conditioned medium appears to be as effective as injected cells in protecting
against kidney injury (5, 18, 24). The specific mediator or mediators responsible for MSC-induced
renoprotection, however, remains to be determined. In an obstructive model of CKD, MSCs have been
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shown to decrease renal TNF-α expression but not effect transforming growth factor (TGF)-β1, VEGF,
IL-10, FGF, or hepatocyte growth factor expression (2), whereas, in a model of diabetic nephropathy,
MSCs appear to reduce renal TGF-β1 expression and signaling while increasing renal BMP-7 production
(18, 24). MSCs have also been demonstrated to increase renal hepatocyte growth factor production in a 5/6
nephrectomy model of CKD (4).
Many of the profibrotic cytokines and growth factors released during CKD are sequestered in the
extracellular matrix in a quiescent state but can be released and made more bioavailable to neighboring
cells with the activity of proteinases such as MMP-9.
MMP-9 is a gelatinase that digests denatured collagens and is critical for ECM remodeling and matrix
homeostasis. While MMP-9 was traditionally thought to have an antifibrotic role in renal fibrosis due to its
proteolytic activity (33), evidence suggests that MMP-9 is an important mediator of renal fibrosis and EMT
during obstructive renal injury independent of TGF-β expression (41). MMP-9 is upregulated in response
to kidney obstruction and has been shown to promote EMT by stimulating E-cadherin shedding and tubular
basement membrane degradation (41, 45). It can also release and activate a variety of profibrotic growth
factors and cytokines sequestered in the ECM upon proteolysis (39). Because MSCs appear to have a
heterogeneous effect on cytokine expression and signaling during CKD, depending on the model of injury,
we sought to investigate the effect of MSCs on matrix regulation as a potential explanation for this variable
response.
Our results demonstrate a dramatic reduction in obstruction-induced MMP-9 and TIMP-1 expression, and
over an eightfold increase in the ratio of TIMP-1 to MMP-9 expression, in the presence of MSCs. These
results support prior observations in the literature that MMP-9 and TIMP-1 expression are increased in
response to obstruction (41, 43) and provide the first report that exogenously delivered MSCs may
stimulate renal protection by reducing MMP-9 expression. Whereas injected MSCs release an array of
protective cytokines and growth factors that likely contribute to renal repair, these results suggest that
another important mechanism of MSC-induced renoprotection may involve a dramatic reduction in
MMP-9-mediated profibrotic mediator release from the ECM and a subsequent reduction in the activation
and bioavailability of these cytokines and growth factors. This effect of MSCs on matrix regulation and
MMP-9 expression could also explain the significant anti-fibrotic properties of MSCs observed during
kidney obstruction despite persistently elevated TGF-β and FGF expression.
Recent reports link MMP-9 expression in mammary epithelial cells and dermal fibroblasts to STAT3
activation (6, 40), and STAT3 has previously been shown to mediate profibrotic signaling in TECs (17, 20)
and tubulointerstitial fibrosis in response to kidney obstruction (17, 23). Despite STAT3′s significant role in
obstruction-induced renal injury, the effect of MSCs on obstruction-induced STAT3 expression has not
previously been evaluated. Our results demonstrate that the presence of MSCs stimulates a significant
reduction in active STAT3 expression during kidney obstruction and suggests that STAT3 has a significant
role in MSC-mediated renoprotection. Given the findings linking MMP-9 expression to STAT3 activation
in other cells, we investigated the effect of STAT3 activation on MMP-9 expression and tubulointerstitial
fibrosis during kidney obstruction. We found that the specific STAT3 inhibitor S3I-201 (23) significantly
reduces active STAT3 and MMP-9 expression in response to kidney obstruction and, further, causes a
significant reduction in obstruction-induced tubulointerstitial fibrosis and collagen and fibronectin
deposition. These findings not only suggest that STAT3 activation contributes to MMP-9 upregulation and
tubulointerstitial fibrosis during kidney obstruction, they suggest that MSCs may reduce MMP-9
expression during UUO through a STAT3-dependent mechanism.
In conclusion, our study demonstrates that MSCs protect against obstruction-induced renal fibrosis and
suggest that their mechanism of action may involve a decrease in STAT3 activation and STAT3-dependent
MMP-9 production. A greater understanding of the interaction between STAT signaling and MMP
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production and the impact of MSCs on matrix regulation during chronic renal injury may facilitate the
application of MSCs in the treatment of CKD.
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Fig. 1.
Quantitative collagen I and III mRNA expression and Masson’s trichrome staining following unilateral ureteral obstruction
(UUO). A: quantitative collagen I mRNA expression represented as a percentage of β-actin in animals exposed to sham
operation in the presence of vehicle (sham) or exogenous mesenchymal stem cells (MSCs) (sham + SC), or 4 wk of UUO
in the presence of vehicle (OB) or MSCs (OB + SC). B: quantitative collagen III mRNA expression represented as a
percentage of β−actin in animals exposed to sham operation in the presence of vehicle or exogenous MSCs, or 4 wk of
UUO in the presence of vehicle or MSCs. C: images depicting collagen deposition (blue stain; arrows) in animals exposed
to sham operation or 4 wk of UUO in the presence of vehicle or MSCs. T, tubule; G, glomerulus. Magnification ×400.
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Fig. 2.
Renal cortical fibronectin and α-smooth muscle actin (α-SMA) expression following UUO. A: gel photograph and
densitometric analysis of fibronectin expression represented as a percentage of GAPDH in animals exposed to sham
operation in the presence of vehicle or exogenous MSCs, or 4 wk of UUO in the presence of vehicle or MSCs. B: gel
photograph and densitometric analysis of α-SMA expression represented as a percentage of GAPDH in animals exposed to
sham operation in the presence of vehicle or exogenous MSCs, or 4 wk of UUO in the presence of vehicle or MSCs.
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Fig. 3.
Renal cortical fibronectin and α-SMA deposition following UUO. Photographs (magnification x400) depicting renal
cortical fibronectin and α-SMA deposition (brown stain; arrows) in animals exposed to sham operation or 4 wk of UUO in
the presence of vehicle or MSCs. Magnification ×400.
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Fig. 4.
Renal cortical matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) protein
expression and quantitative MMP-9 mRNA expression following UUO. A: MMP-9 protein levels in animals exposed to
sham operation in the presence of vehicle or exogenous MSCs, or 4 wk of UUO in the presence of vehicle or MSCs. B:
quantitative MMP-9 mRNA expression represented as a percentage of β−actin in animals exposed to sham operation in the
presence of vehicle or exogenous MSCs, or 4 wk of UUO in the presence of vehicle or MSCs. C: TIMP-1 protein levels in
animals exposed to sham operation in the presence of vehicle or exogenous MSCs, or 4 wk of UUO in the presence of
vehicle or MSCs. D: ratio of TIMP-1/MMP-9 protein levels in animals exposed to sham operation in the presence of
vehicle or exogenous MSCs, or 4 wk of UUO in the presence of vehicle or MSCs.
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Fig. 5.
Open in a separate window
Renal cortical active STAT3 (p-STAT3) protein expression and immunolocalization following UUO. A: gel photograph and
densitometric analysis of p-STAT3 expression represented as a percentage of GAPDH in animals exposed to sham
operation in the presence of vehicle or exogenous MSCs, or 4 wk of UUO in the presence of vehicle or MSCs. B:
photographs depicting renal cortical STAT3 (brown stain; arrows) in animals exposed to sham operation or 4 wk of UUO
in the presence of vehicle or MSCs. Magnification ×400.
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Fig. 6.
Effect of S3I-201 on renal cortical p-STAT3 and MMP-9 protein expression following UUO. A: gel photograph and
densitometric analysis of p-STAT3 expression represented as a percentage of GAPDH in animals exposed to sham
operation or 2 wk of UUO in the presence of vehicle or S3I-201 (OB + S3I-201). B: MMP-9 protein levels in animals
exposed to sham operation or 2 wk of UUO in the presence of vehicle or S3I-201.
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Fig. 7.
Effect of S3I-201 on renal cortical collagen and fibronectin deposition following UUO. Photographs (magnification ×400)
depicting renal cortical collagen deposition (Masson’s trichrome, blue stain, arrows) and fibronectin deposition (brown
stain, arrow) in animals exposed to sham operation (sham) or 2 wk of UUO in the presence of vehicle (OB) or S3I-201
(OB + S3I-201). Magnification ×400.
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